Seres Therapeutics

Seres Therapeutics is a commercial-stage biotechnology company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The company is pioneering a new class of medicines designed to modulate the human microbiome, the trillions of microbes that live in or on the body, with the goal of treating and preventing a wide range of diseases.

Seres' key focus is on developing therapies for individuals with compromised immune systems and/or disrupted gastrointestinal microbiomes, who are at a high risk of serious infections. Their lead product, SER-155, is currently being evaluated in a Phase 1b study for patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) and is designed to prevent gastrointestinal-derived infections and resulting bloodstream infections. The company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants.

Seres Therapeutics is a commercial biotechnology company dedicated to improving patient health through innovative microbiome therapeutics. Their mission is to revolutionize the treatment of a wide range of diseases by modulating the function of the human microbiome, ultimately transforming the lives of patients worldwide.

Seres Therapeutics cultivates a collaborative and innovative culture, prioritizing teamwork and a shared passion for improving patient lives through microbiome therapeutics. The company values courage, deep collaboration, and a commitment to groundbreaking discoveries, fostering an environment where diverse expertise and insights drive progress and change the face of medicine.